nach oben

Erschienen in:

11.07.2016 | Topic Review

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge

verfasst von: Daniel N. Cagney, Brian M. Alexander, F. Stephen Hodi, Elizabeth I. Buchbinder, Patrick A. Ott, Ayal A. Aizer

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Novel systemic therapies with anti-tumor activity in the brain including small molecules targeting BRAF and MEK, and immune checkpoint inhibition, offer the possibility of improved control of intracranial disease. A number of prospective trials support the judicious use of modern systemic therapies in patients with melanoma and limited brain metastases .The intracranial clinical course of patients who progress extracranially on BRAF/MEK inhibition remains poorly described in the literature. In this report, we highlight a series of clinical cases, with rapid progression of intracranial disease following discontinuation of dabrafenib/trametinib for extracranial disease progression or toxicity, a previously unreported finding in the medical literature with significant implications for patient care.

Chiarion-Sileni V, Murr R, Pigozzo J (2001) Brain metastases from malignant melanoma. Int Soc Cell 13:170–185

Tarhini AA, Agarwala SS (2004) Management of brain metastases in patients with melanoma. Curr Opin Oncol 16:61–166CrossRef

Ott PA, Hodi FS (2013) Treatment for advanced melanoma: new drugs, new opportunities, new challenges. Oncology (Williston Park) 27(5):381–392

Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ et al (2008) Metaanalysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26:527–534CrossRefPubMed

Schmittel A, Proebstle T, Engenhart-Cabillic R (2003) Brain metastases following interleukin-2 plus interferon-alpha-2a therapy: a follow-up study in 94 stage IV melanoma patients. Eur J Cancer 39:476–480CrossRefPubMed

Chang EL et al (2009) Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 10(11):1037–1044CrossRefPubMed

Kocher M et al (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 29(2):134–141CrossRefPubMed

Soffietti R et al (2013) A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. J Clin Oncol 31(1):65–72CrossRefPubMed

Kolar GR et al (2013) Neoadjuvant treatment of a solitary melanoma brain metastasis with vemurafenib. J Clin Oncol 31(3):e40–e43CrossRefPubMed

10.

Schäfer N et al (2013) Vemurafenib for leptomeningeal melanomatosis. J Clin Oncol 31(11):e173–e174CrossRefPubMed

11.

Falchook GS et al (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379(9829):1893–1901CrossRefPubMedPubMedCentral

12.

Long V et al (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13(11):1087–1095CrossRefPubMed

13.

Sosman A et al (2012) Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib. N Engl J Med 366(8):707–714CrossRefPubMedPubMedCentral

14.

Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507–2516CrossRefPubMedPubMedCentral

15.

Flaherty KT et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363(9):809–819CrossRefPubMedPubMedCentral

16.

Flaherty KT et al (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367(18):1694–1703CrossRefPubMedPubMedCentral

17.

Long GV et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 37(120):1877–1888CrossRef

18.

Robert C et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372(1):30–39CrossRefPubMed

19.

Carlino MS, Gowrishankar K, Saunders CA et al (2013) Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma. Mol Cancer Ther 12:1332CrossRefPubMed

20.

Menzies AM, Long GV (2014) Systemic treatment for BRAF-mutant melanoma: where do we go next? Lancet Oncol 15:e371CrossRefPubMed

21.

Jakob JA et al (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118(16):4014–4023CrossRefPubMed

22.

Kumar R et al (2003) BRAF Mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9(9):3362–3368PubMed

23.

Scholtens A, Geukes Foppen MH, Blank CU, van Thienen JV, van Tinteren H, Haanen JB (2015) Vemurafenib for BRAF V600 mutated advanced melanoma: Results of treatment beyond progression. Eur J Cancer 51:642–652CrossRefPubMed

24.

Cancello G, Montagna E, D’Agostino D, Giuliano M, Giordano A, Di Lorenzo G et al (2008) Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 10(4):R60.CrossRefPubMedPubMedCentral

25.

Faehling M, Eckert R, Kamp T, Kuom S, Griese U, Strater J et al (2013) EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Lung Cancer 80(3):306–312CrossRefPubMed

26.

Grothey A, Sugrue MM, Purdie DM, Dong W, Sargent D, Hedrick E et al (2008) Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26(33):5326–5334CrossRefPubMed

Titel: Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge
verfasst von: Daniel N. Cagney
Brian M. Alexander
F. Stephen Hodi
Elizabeth I. Buchbinder
Patrick A. Ott
Ayal A. Aizer
Publikationsdatum: 11.07.2016
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 3/2016
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2196-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

25.04.2024 | Hypotonie | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Rapid progression of intracranial melanoma metastases controlled with combined BRAF/MEK inhibition after discontinuation of therapy: a clinical challenge

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Coexistence of MLH3 germline variants in colon cancer patients belonging to families with Lynch syndrome-associated brain tumors

Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors

Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy

A molecular biology and phase II study of imetelstat (GRN163L) in children with recurrent or refractory central nervous system malignancies: a pediatric brain tumor consortium study

Impact of tapering and discontinuation of bevacizumab in patients with progressive glioblastoma

Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg)

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Update Neurologie